What is Roth Capital’s Estimate for ZVRA FY2029 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at Roth Capital issued their FY2029 earnings estimates for Zevra Therapeutics in a report issued on Sunday, February 9th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings of $2.26 per share for the year. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

Several other research firms have also recently weighed in on ZVRA. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, Cantor Fitzgerald upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Zevra Therapeutics presently has a consensus rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Stock Up 2.4 %

Shares of NASDAQ ZVRA opened at $7.72 on Tuesday. The stock has a market capitalization of $412.06 million, a P/E ratio of -3.92 and a beta of 2.00. The company has a 50-day moving average price of $8.26 and a 200-day moving average price of $8.03. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter in the prior year, the business earned ($0.40) earnings per share.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently modified their holdings of ZVRA. The Manufacturers Life Insurance Company lifted its stake in shares of Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in Zevra Therapeutics in the 2nd quarter worth approximately $474,000. SG Americas Securities LLC purchased a new stake in Zevra Therapeutics in the 3rd quarter worth approximately $105,000. City State Bank lifted its stake in Zevra Therapeutics by 14.1% in the 3rd quarter. City State Bank now owns 16,224 shares of the company’s stock worth $113,000 after purchasing an additional 2,000 shares in the last quarter. Finally, IFG Advisors LLC lifted its stake in Zevra Therapeutics by 41.2% in the 3rd quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock worth $183,000 after purchasing an additional 7,700 shares in the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.